Treatments for Plaque Psoriasis

A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments.

This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.

Adalimumab may be effective for plaque psoriasis, but not heart disease and other inflammatory conditions associated with the condition. This study confirms that the inflammatory process is unique and that one treatment may not apply to other inflammatory conditions.

Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.

The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD. 

Physicians may want to reconsider goals for the treatment of plaque psoriasis. In this study, physicians describe utilizing treat-to-target with a patient-centered approach to care for symptom relief.

As the list of treatments for plaque psoriasis grows, so does the list of adverse events associated with biologic treatment. In this article, we summarize adverse events associated with common treatments for plaque psoriasis.

Brodalumab most cost-effective with high efficacy for plaque psoriasis, but IL-17 inhibitors as a whole outperform other biologics, study shows.  

Twice-monthly certolizumab for plaque psoriasis could prove to be an option for patients who struggle with twice-weekly dosing, a study shows.

"Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians," researchers write in Seminars in Cutaneous Medicine and Surgery.

A study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe

While there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.

Physicians should be aware of the warning signs that a biologic agent could be to blame when patients experience subacute or rapidly progressive neurologic changes, researchers say.

Acute or irregular flushing may signal a more serious health condition, say researchers who list 14 questions physicians should ask patients complaining about unusual flushing.

A small study shows that ultrasound may be a viable diagnostic tool to determine whether patients have psoriasis or psoriatic arthritis, Italian researchers report.

A JAMA Dermatology study raises the possibility of adopting the NASH FibroSure test to detect hepatic fibrosis in psoriasis patients and minimize the number of liver biopsies.

Fear associated with perceived pain from injectable biologics has been shown to be successfully addressed by employing anchoring bias interventions, researchers report in JAMA Dermatology.

The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.

NEJM analysis proves what has been suspected for decades: Alcohol can be more deadly in the psoriasis population as compared to non-psoriasis patients.

Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.

A retrospective review of pediatric patients treated for psoriasis with systemic agents provides much needed insight about the safety and tolerability of these medications.

Survey highlights the challenges of controlling psoriasis flares.

Experts from around the world will gather in London at the Psoriasis from Gene to Clinic Congress to present and discuss the most current developments in the understanding of psoriasis and the evidence that will steer future clinical decision making. Watch here for highlights.

The American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.

Switching from originator to biosimilar shows no significant impact on drug survival in plaque psoriasis, but outcomes differ, researchers report.

A pediatric dermatologist addresses important differences in children with psoriasis, versus adults.

The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (©FreeBirdPhotos/Shutterstock.com)

New research offers strong evidence that vascular inflammation and risk of having a major adverse cardiovascular event increases with psoriasis duration.

Of several biologic agents that women of reproductive age can choose from to treat and manage psoriasis, not all have the same safety profile during pregnancy and lactation periods.